Breast Cancer Risk Score and Hyperplasia Medical Management Process

These are the process steps for breast cancer risk assessment and medical management when the BBDRisk Dx™ test is completed and results have been finalized.

Step 1: First, The BBDRisk Dx™ test assesses multiple cancer proteins in the patient’s tumor tissue which was previously biopsied and diagnosed to have one or more of the following: Atypical Ductal Hyperplasia (ADH), Atypical Lobular Hyperplasia (ALH), Usual Ductal Hyperplasia (UDH), Papilloma (PAP), or Sclerosing Adenosis.

Step 2: Second, based on the cancer marker levels in the tumor tissue, a ‘Cancer Risk Score’ in the range of 0-10 will be provided. The higher the risk score, the higher one’s risk of developing breast cancer.

Medical Management For Elevated And High Risk Test Scores

Step 3. Third, based on the ‘Risk Score’ a patient will be categorized as ‘Low Risk’, ‘Intermediate Risk’ or ‘Elevated (High) Risk’ for developing breast cancer in the future.

Step 4. Fourth, the test Results Report will provide an overview of the ‘Cancer Free Rate or Cancer Rate’ over 5-10 years among women who have a similar ‘Risk Score’ from the test validation study.

Step 5. Fifth, medical management decisions can be made based on the ‘Cancer Risk Score’ and consultation between each patient and his or her healthcare professional (Figure below).

 

 

 

For example, standard screening for women with atypical as well as non-atypical tumors whose BBDRisk Dx™ results indicate a “Low Risk” of developing cancer. If BBDRisk Dx™ results indicate that a patient has an Intermediate or Elevated Risk of developing breast cancer, the following medical management options that are currently approved for women with atypias may help reduce risk by 1) detecting it at an earlier more treatable stage, 2) delaying the onset of cancer, or 3) preventing the development of cancer over the long term:

  • Increased surveillance
  • Risk-reducing medications and/or
  • Prophylactic surgery

Disclaimer: Any discussion of medical management options provided here are for general informational purposes only and should not be interpreted as recommendations by Silbiotech, Inc. While BBDRisk Dx™ test results provide useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare professional. The patient and his or her doctor are solely responsible for making any medical management decisions.